Search Results: Prevention, Detection & Risk + Prostate Cancer (8 results)
Men at High Genetic Risk for Prostate Cancer
https://www.facingourrisk.org/research-clinical-trials/study/72/men-at-high-genetic-risk-for-prostate-cancer
Prevention
Prostate screening with MRI for men with Lynch syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM) or a BRCA1, BRCA2, HOXB13, ATM, NBN, TP53, BRIP1, CHEK2, PALB2, RAD51C, RAD51D, or other mutation
The National Institutes of Health has a clinical trial for men at high genetic risk for prostate cancer. This is trial is for men without prostate cancer, ages 30 to 75, who have tested positive for Lynch syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM) or BRCA1, BRCA2, HOXB13, ATM, NBN, TP53, BRIP1, CHEK2, PALB2, RAD51C, RAD51D, or FANC (FANCA, FANCB, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, and FANCM). The trial involves screening MRI of the prostate every two years and biopsy of the prostate if the MRI is abnormal. There is no cost for travel or study-related tests.
PATROL Study: Prostate Cancer Screening for People AT Genetic Risk FOr Aggressive Disease
https://www.facingourrisk.org/research-clinical-trials/study/291/patrol-study-prostate-cancer-screening-for-people-at-genetic-risk-for-aggressive-disease
Prevention
Screening study for people with a mutation linked to prostate cancer risk
The PATROL (Prostate Cancer Screening for People AT Genetic Risk FOr Aggressive Disease) study is for people at risk for prostate cancer because they carry one or more genes that are known or suspected to increase prostate cancer risk: BRCA2, HOXB13, ATM, BRCA1, MLH1, MSH2, MSH6, PALB2, PMS2, CHEK2, RAD51D, or TP53.
MRI Screening in Men at High Risk of Developing Prostate Cancer
https://www.facingourrisk.org/research-clinical-trials/study/260/screening-in-men-at-high-risk-of-developing-prostate-cancer
Prevention
Screening using MRI for men at risk of developing prostate cancer
This study will determine if prostate magnetic resonance imaging (MRI) will find prostate cancer in men at high risk of developing prostate cancer.
Testing a Vaccine for Cancer Prevention in People with a BRCA1 or BRCA2 Mutation
https://www.facingourrisk.org/research-clinical-trials/study/172/testing-a-vaccine-for-cancer-prevention-in-people-with-a-brca1-or-brca2-mutation
Prevention
People with a BRCA1 or BRCA2 mutation
This study will look at a new vaccine known as INO-5401 used alone or combined with a second vaccine called INO-9012. The study will test if the vaccine is safe (without large side effects) and test a new way of giving vaccines. It will also test whether the vaccine activates the immune system. A goal of this research is to reduce cancer risk in people with a BRCA1 or BRCA2 mutation. Additional studies will be needed to learn if this vaccine approach lowers cancer risk in mutation carriers.
Prostate Cancer Genetic Risk Evaluation and Screening Study (PROGRESS)
https://www.facingourrisk.org/research-clinical-trials/study/180/prostate-cancer-genetic-risk-evaluation-and-screening-study-progress
Prevention
People at high risk for prostate cancer due to an inherited mutation
This study will look at how enhanced prostate cancer screening using MRI will improve early detection rates and further understanding of how inherited mutations can lead to development of prostate cancer.
Upright MRI for Prostate Cancer Screening
https://www.facingourrisk.org/research-clinical-trials/study/259/upright-mri-for-prostate-cancer-screening
Prevention
Screening for prostate cancer using upright MRI
This study will compare the effectiveness of an upright magnetic resonance imaging (MRI) compared to prostate specific antigen (PSA) and current MRI imaging for prostate cancer screening.
IGNITE-TX - Identifying Individuals for Genetic Testing for Familial Cancer
https://www.facingourrisk.org/research-clinical-trials/study/266/helping-people-with-a-genetic-mutation-in-brca1-brca2-or-lynch-syndrome-talk-to-their-family-members-about-their-risk-for-cancer-and-find-the-best-way-to-get-family-members-tested
Prevention
People with a genetic mutation in BRCA1, BRCA2 or Lynch syndrome who have relatives who have not been tested
The IGNITE-TX study is all about helping people with a genetic mutation in BRCA1, BRCA2 or Lynch syndrome talk to their family members about their risk for cancer and find the best way to get family members tested.
Genomic Services Research Program Study for People with Unexpected Genetic Results
https://www.facingourrisk.org/research-clinical-trials/study/89/study-for-people-with-unexpected-genetic-results
Prevention
A new study is recruiting people who received unexpected genetic test results about their cancer risk after having genetic testing done for some other reason.
This is a study of people with "secondary results” from genetic testing. Secondary results are unexpected. They are not related to the reason the person had the genetic test but are shared because they may be very important to the person’s health. Most secondary results have to do with high risks for health problems that can be treated or prevented. Many of these results are related to cancer risk. If you think you have received a secondary result, you may be eligible to join this study.
Additional Results on Clinicaltrials.gov Prevention, Detection & Risk + Prostate Cancer
12 results
MRI Screening in Men at High Risk of Developing Prostate Cancer
NCT ID: NCT05608694 (https://classic.clinicaltrials.gov/show/NCT05608694)
Utility of Biparametric MRI (Magnetic Resonance Imaging) as a Screening Tool for Prostate Cancer in a High-Risk Cohort
NCT ID: NCT05384535 (https://classic.clinicaltrials.gov/show/NCT05384535)
Prostate Cancer Genetic Risk Evaluation and Screening Study
NCT ID: NCT05129605 (https://classic.clinicaltrials.gov/show/NCT05129605)
Upright MRI for Prostate Cancer Screening
NCT ID: NCT03474913 (https://classic.clinicaltrials.gov/show/NCT03474913)
Optimizing Timing of rhPSMA-7.3 (18F) for Assessing Site(s) of Recurrent Disease Following Radical Prostatectomy
NCT ID: NCT05678322 (https://classic.clinicaltrials.gov/show/NCT05678322)
Men Moving Forward: A Lifestyle Program for African-American Prostate Cancer Survivors
NCT ID: NCT03971591 (https://classic.clinicaltrials.gov/show/NCT03971591)
African Cancer Genome: GMD
NCT ID: NCT05754658 (https://classic.clinicaltrials.gov/show/NCT05754658)
The CArdiovascular Risk Evaluation in Men With Prostate Cancer Study (CARE-PC) Pilot Feasibility Study
NCT ID: NCT06064149 (https://classic.clinicaltrials.gov/show/NCT06064149)
The Effect of IBD Flares on Serum PSA
NCT ID: NCT03558048 (https://classic.clinicaltrials.gov/show/NCT03558048)
MRI Fusion Biopsy vs. Micro-Ultrasound Guided Biopsy
NCT ID: NCT05471128 (https://classic.clinicaltrials.gov/show/NCT05471128)
The Genomic Medicine at VA Study
NCT ID: NCT04331535 (https://classic.clinicaltrials.gov/show/NCT04331535)
PReclude Infection EVEnts With No Prophylaxis Transperineal Biopsy 2
NCT ID: NCT04815876 (https://classic.clinicaltrials.gov/show/NCT04815876)
About FORCE
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.